Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
CNBC
—
The aestetics company hope increased GLP-1 use will fuel demand for treatments addressing facial volume loss, sometimes dubbed "Ozempic face."